# Macquarie Equities Research



# The Global Property Specialist

# INDIA

# India real estate sector Innocuous clause- serious implication

### Event

 The foreign investment policy update was released last week by the Indian government. An innocuous clause in the document changes the classification of any investment with an option from FDI (Foreign Direct Investment) to ECB (External Commercial Borrowing). This has far-reaching implications for the Indian real estate sector since ECBs are not allowed in real estate in India and most foreign equity investments have built-in options.

### Impact

- Clause reflecting the revised FDI policy stance: The clause in the policy document says that "Only equity shares, fully, compulsorily and mandatorily convertible debentures/ preference shares, with no in-built options of any type, would qualify as eligible instruments for FDI. Equity instruments having in-built options or supported by options sold by third parties would lose their equity character and such instruments would have to comply with ECB guidelines". We present the implications of this move.
- Future flows would get impacted: ECBs are not permitted in Indian real estate. Put options in private equity or compulsorily convertible bonds are the norm while investing in real estate projects as they offer some protection and an exit avenue. We think many investors would re-consider investing or change their return expectations if these options are not offered.
- Policy has been a moving target: This move is the latest in a series of changes which has started to frustrate foreign private equity investors. Last week we attended a real estate industry conference. The encouraging aspect was that a few funds have un-deployed capital. However they are finding it tough to invest due to an "elevated risk profile". Two private equity fund managers mentioned that this is due to the fluid scenario of regulations and their interpretation. They mentioned that the consistent news flow on the anti-corruption protests and "policy inaction" had led to their foreign investors starting to re-consider their intention of deploying money in India. (See our series of notes from 30 September to 3 October 2011).
- Typically, a private equity investor would be very active in the prevailing stress. But the environment is making it tough for them to pull the trigger.
- Will past deals get impacted? Importantly, it is not clear whether this reclassification will be applicable with retrospective effect. If that is the case, barring very few exceptions, all private equity deals done in the real estate sector since 2005 would be affected. Some examples of developers who have received FDI are DLF, Ansal, Parsvnath, Nitesh, Prestige, Ackruti and Godrej Properties. This would also involve many unlisted developers. While we think this will get resolved eventually, there may be near term concerns/ overhang regarding change in the structure of deals or pressure from private equity investors to exit.

#### Unmesh Sharma, CFA +91 22 6720 4092 unmesh.sharma@macquarie.com

Kumar Saurabh +91 22 6720 4091 kumar.saurabh@macquarie.com

5 October 2011 Macquarie Capital Securities India (Pvt) Ltd

### Outlook

 This latest change leads to further stress and uncertainty for the Indian real estate sector, in our view. We would avoid players with high leverage and weak cash flow yields.

Please refer to the important disclosures and analyst certification on inside back cover of this document, or on our website www.macquarie.com.au/disclosures.

### Fig 1 India property coverage snapshot

	Μ	Market Cap		Price	TP	Upside	NAV/sh	Disc	TP disc	
Company	Ticker	(US\$m)	Rating	(Rs)	(Rs)	. (%)	(Rs)	to NAV	to NAV	WAC
NCR based compared	nies									
DLF	DLFU IN	7,080	OP	201	302	50.4%	377	-47%	-20%	14.79
Unitech	UT IN	1,358	Ν	25	30	18.1%	59	-58%	-50%	14.79
JIL	JPIN IN	1,410	Ν	48	43	-10.5%	86	-44%	-30%	15.29
Anant Raj	ARCP IN	332	OP	53	108	103.8%	180	-71%	-40%	15.1%
Ansal API	APIL IN	106	Ν	33	49	51.4%	82	-60%	-40%	16.0%
Omaxe	OAXE IN	477	UP	135	92	-31.6%	153	-12%	-40%	16.0%
Mumbai based com	panies									
HDIL	HDIL IN	783	OP	90	230	155.5%	306	-71%	-25%	15.1%
DB Realty	DBRL IN	246	OP	49	172	252.5%	344	-86%	-50%	15.1%
IBREL	IBREL IN	583	UP	70	101	27.0%	144	-43%	-30%	15.1%
Phoenix	PHNX IN	613	OP	210	270	28.8%	338	-38%	-20%	15.1%
Bangalore based co	ompanies									
Prestige	PEPL IN	590	OP	88	210	138.9%	263	-67%	-20%	15.1%
Sobha	SOBHA IN	416	OP	207	430	108.4%	538	-62%	-20%	15.1%
Source: Bloomberg	, Macquarie Researc	h, October 20	011							

Share price date 4 October 2011

## Other stocks mentioned in this report:

Parsvanath Developers - PARSV IN, CMP-Rs64, Not Rated

Nitesh Estates - NITE IN, CMP-Rs16, Not Rated

Ackruti - AKCL IN, Rs189, Not Rated

Godrej Properties - GPL IN, Rs649, Not Rated

#### **Macquarie Research**

#### Important disclosures:

#### Recommendation definitions

Macquarie - Australia/New Zealand Outperform – return >3% in excess of benchmark return Neutral – return within 3% of benchmark return Underperform – return >3% below benchmark return

Benchmark return is determined by long term nominal GDP growth plus 12 month forward market dividend yield

#### Macquarie - Asia/Europe

Outperform - expected return >+10% Neutral - expected return from -10% to +10% Underperform - expected return <-10%

#### Macquarie First South - South Africa

Outperform - expected return >+10% Neutral - expected return from -10% to +10% Underperform - expected return <-10%

#### Macquarie - Canada

Outperform - return >5% in excess of benchmark return Neutral – return within 5% of benchmark return Underperform – return >5% below benchmark return

#### Macquarie - USA

Outperform (Buy) - return >5% in excess of Russell 3000 index return Neutral (Hold) - return within 5% of Russell 3000 index return

Underperform (Sell)- return >5% below Russell 3000 index return

#### Volatility index definition\*

This is calculated from the volatility of historical price movements.

Very high-highest risk - Stock should be expected to move up or down 60-100% in a year - investors should be aware this stock is highly speculative.

High - stock should be expected to move up or down at least 40-60% in a year - investors should be aware this stock could be speculative.

Medium - stock should be expected to move up or down at least 30-40% in a year.

Low-medium - stock should be expected to move up or down at least 25-30% in a year.

Low - stock should be expected to move up or down at least 15-25% in a year. \* Applicable to Australian/NZ/Canada stocks only

Recommendations - 12 months Note: Quant recommendations may differ from

Fundamental Analyst recommendations

**Financial definitions** 

All "Adjusted" data items have had the following adjustments made:

Added back: goodwill amortisation, provision for catastrophe reserves, IFRS derivatives & hedging, IFRS impairments & IFRS interest expense Excluded: non recurring items, asset revals, property revals, appraisal value uplift, preference dividends & minority interests

#### EPS = adjusted net profit / efpowa\*

number of shares

ROA = adjusted ebit / average total assets ROA Banks/Insurance = adjusted net profit /average total assets ROE = adjusted net profit / average shareholders funds Gross cashflow = adjusted net profit + depreciation \*equivalent fully paid ordinary weighted average

All Reported numbers for Australian/NZ listed stocks are modelled under IFRS (International Financial Reporting Standards).

#### Recommendation proportions - For quarter ending 30 September 2011

	AU/NZ	Asia	RSA	USA	CA	EUR
Outperform	57.35%	65.88%	56.94%	46.54%	74.68%	47.85% (for US coverage by MCUSA, 11.63% of stocks covered are investment banking clients)
Neutral	31.99%	20.68%	31.94%	50.00%	23.42%	34.66% (for US coverage by MCUSA, 9.30% of stocks covered are investment banking clients)
Underperform	10.66%	13.45%	11.11%	3.46%	1.90%	17.49% (for US coverage by MCUSA, 0.47% of stocks covered are investment banking clients)

#### **Company Specific Disclosures:**

Important disclosure information regarding the subject companies covered in this report is available at www.macquarie.com/disclosures.

#### Analyst Certification:

The views expressed in this research accurately reflect the personal views of the analyst(s) about the subject securities or issuers and no part of the compensation of the analyst(s) was, is, or will be directly or indirectly related to the inclusion of specific recommendations or views in this research. The analyst principally responsible for the preparation of this research receives compensation based on overall revenues of Macquarie Group Ltd ABN 94 122 169 279 (AFSL No. 318062) (MGL) and its related entities (the Macquarie Group) and has taken reasonable care to achieve and maintain independence and objectivity in making any recommendations.

#### **General Disclaimers:**

Macquarie Securities (Australia) Ltd; Macquarie Capital (Europe) Ltd; Macquarie Capital Markets Canada Ltd; Macquarie Capital Markets North America Ltd; Macquarie Capital (USA) Inc; Macquarie Capital Securities Ltd and its Taiwan branch; Macquarie Capital Securities (Singapore) Pte Ltd; Macquarie Securities (NZ) Ltd; Macquarie First South Securities (Pty) Limited; Macquarie Capital Securities (India) Pvt Ltd; Macquarie Capital Securities (Malaysia) Sdn Bhd; Macquarie Securities Korea Limited and Macquarie Securities (Thailand) Ltd are not authorized deposit-taking institutions for the purposes of the Banking Act 1959 (Commonwealth of Australia), and their obligations do not represent deposits or other liabilities of Macquarie Bank Limited ABN 46 008 583 542 (MBL) or MGL. MBL does not guarantee or otherwise provide assurance in respect of the obligations of any of the above mentioned entities. MGL provides a guarantee to the Monetary Authority of Singapore in respect of the obligations and liabilities of Macquarie Capital Securities (Singapore) Pte Ltd for up to SGD 35 million. This research has been prepared for the general use of the wholesale clients of the Macquarie Group and must not be copied, either in whole or in part, or distributed to any other person. If you are not the intended recipient you must not use or disclose the information in this research in any way. If you received it in error, please tell us immediately by return e-mail and delete the document. We do not guarantee the integrity of any e-mails or attached files and are not responsible for any changes made to them by any other person. MGL has established and implemented a conflicts policy at group level (which may be revised and updated from time to time) (the "Conflicts Policy") pursuant to regulatory requirements (including the FSA Rules) which sets out how we must seek to identify and manage all material conflicts of interest. Nothing in this research shall be construed as a solicitation to buy or sell any security or product, or to engage in or refrain from engaging in any transaction. In preparing this research, we did not take into account your investment objectives, financial situation or particular needs. Before making an investment decision on the basis of this research, you need to consider, with or without the assistance of an adviser, whether the advice is appropriate in light of your particular investment needs, objectives and financial circumstances. There are risks involved in securities trading. The price of securities can and does fluctuate, and an individual security may even become valueless. International investors are reminded of the additional risks inherent in international investments, such as currency fluctuations and international stock market or economic conditions, which may adversely affect the value of the investment. This research is based on information obtained from sources believed to be reliable but we do not make any representation or warranty that it is accurate, complete or up to date. We accept no obligation to correct or update the information or opinions in it. Opinions expressed are subject to change without notice. No member of the Macquarie Group accepts any liability whatsoever for any direct, indirect, consequential or other loss arising from any use of this research and/or further communication in relation to this research. Clients should contact analysts at, and execute transactions through, a Macquarie Group entity in their home jurisdiction unless governing law permits otherwise.

#### **Country-Specific Disclaimers:**

Australia: In Australia, research is issued and distributed by Macquarie Securities (Australia) Ltd (AFSL No. 238947), a participating organisation of the Australian Securities Exchange. New Zealand: In New Zealand, research is issued and distributed by Macquarie Securities (NZ) Ltd, a NZX Firm. Canada: In Canada, research is prepared, approved and distributed by Macquarie Capital Markets Canada Ltd, a participating organisation of the Toronto Stock Exchange, TSX Venture Exchange & Montréal Exchange. Macquarie Capital Markets North America Ltd., which is a registered brokerdealer and member of FINRA, accepts responsibility for the contents of reports issued by Macquarie Capital Markets Canada Ltd in the United States and sent to US persons. Any person wishing to effect transactions in the securities described in the reports issued by Macquarie Capital Markets Canada Ltd should do so with Macquarie Capital Markets North America Ltd. The Research Distribution Policy of Macquarie Capital Markets Canada Ltd is to allow all clients that are entitled to have equal access to our research. United Kingdom: In the United Kingdom, research is issued and distributed by Macquarie Capital (Europe) Ltd, which is authorised and regulated by the Financial Services Authority (No. 193905). Germany: In Germany, research is issued and distributed by Macquarie Capital (Europe) Ltd, Niederlassung Deutschland, which is authorised and regulated in the United Kingdom by the Financial Services Authority (No. 193905). France: In France, research is issued and distributed by Macquarie Capital (Europe) Ltd, which is authorised and regulated in the United Kingdom by the Financial Services Authority (No. 193905). Hong Kong & Mainland China: In Hong Kong, research is issued and distributed by Macquarie Capital Securities Ltd, which is licensed and regulated by the Securities and Futures

#### **Macquarie Research**

Commission. In Mainland China, Macquarie Securities (Australia) Limited Shanghai Representative Office only engages in non-business operational activities excluding issuing and distributing research. Only non-A share research is distributed into Mainland China by Macquarie Capital Securities Ltd. Japan: In Japan, research is issued and distributed by Macquarie Capital Securities (Japan) Limited, a member of the Tokyo Stock Exchange, Inc. and Osaka Securities Exchange Co. Ltd (Financial Instruments Firm, Kanto Financial Bureau (kin-sho) No. 231, a member of Japan Securities Dealers Association and Financial Futures Association of Japan and Japan Securities Investment Advisers Association). India: In India, research is issued and distributed by Macquarie Capital Securities (India) Pvt Ltd., 92, Level 9, 2 North Avenue, Maker Maxity, Bandra Kurla Complex, Bandra (East), Mumbai 400 051, India, which is a SEBI registered Stock Broker having membership with National Stock Exchange of India Limited (INB231246738) and Bombay Stock Exchange Limited (INB011246734). Malaysia: In Malaysia, research is issued and distributed by Macquarie Capital Securities (Malaysia) Sdn. Bhd. (Company registration number: 463469-W) which is a Participating Organisation of Bursa Malaysia Berhad and a holder of Capital Markets Services License issued by the Securities Commission. Taiwan: Information on securities/instruments that are traded in Taiwan is distributed by Macquarie Capital Securities Ltd, Taiwan Branch, which is licensed and regulated by the Financial Supervisory Commission. No portion of the report may be reproduced or quoted by the press or any other person without authorisation from Macquarie. Nothing in this research shall be construed as a solicitation to buy or sell any security or product. Thailand: In Thailand, research is issued and distributed by Macquarie Securities (Thailand) Ltd, a licensed securities company that is authorized by the Ministry of Finance, regulated by the Securities and Exchange Commission of Thailand and is an exchange member no. 28 of the Stock Exchange of Thailand. The Thai Institute of Directors Association has disclosed the Corporate Governance Report of Thai Listed Companies made pursuant to the policy of the Securities and Exchange Commission of Thailand. Macquarie Securities (Thailand) Ltd does not endorse the result of the Corporate Governance Report of Thai Listed Companies but this Report can be accessed at: http://www.thaiiod.com/en/publications.asp?type=4. South Korea: In South Korea, unless otherwise stated, research is prepared, issued and distributed by Macquarie Securities Korea Limited, which is regulated by the Financial Supervisory Services. Information on analysts in MSKL is disclosed at http://dis.kofia.or.kr/fs/dis2/fundMgr/DISFundMgrAnalystPop.jsp?companyCd2=A03053&pageDiv=02. South Africa: In South Africa, research is issued and distributed by Macquarie First South Securities (Pty) Limited, a member of the JSE Limited. Singapore: In Singapore, research is issued and distributed by Macquarie Capital Securities (Singapore) Pte Ltd (Company Registration Number: 198702912C), a Capital Markets Services license holder under the Securities and Futures Act to deal in securities and provide custodial services in Singapore. Pursuant to the Financial Advisers (Amendment) Regulations 2005, Macquarie Capital Securities (Singapore) Pte Ltd is exempt from complying with sections 25, 27 and 36 of the Financial Advisers Act. All Singapore-based recipients of research produced by Macquarie Capital (Europe) Limited, Macquarie Capital Markets Canada Ltd, Macquarie First South Securities (Pty) Limited and Macquarie Capital (USA) Inc. represent and warrant that they are institutional investors as defined in the Securities and Futures Act. United States: In the United States, research is issued and distributed by Macquarie Capital (USA) Inc., which is a registered broker-dealer and member of FINRA. Macquarie Capital (USA) Inc, accepts responsibility for the content of each research report prepared by one of its non-US affiliates when the research report is distributed in the United States by Macquarie Capital (USA) Inc. Macquarie Capital (USA) Inc.'s affiliate's analysts are not registered as research analysts with FINRA, may not be associated persons of Macquarie Capital (USA) Inc., and therefore may not be subject to FINRA rule restrictions on communications with a subject company, public appearances, and trading securities held by a research analyst account. Any persons receiving this report directly from Macquarie Capital (USA) Inc. and wishing to effect a transaction in any security described herein should do so with Macquarie Capital (USA) Inc. Important disclosure information regarding the subject companies covered in this report is available at www.macquarie.com/research/disclosures, or contact your registered representative at 1-888-MAC-STOCK, or write to the Supervisory Analysts, Research Department, Macquarie Securities, 125 W.55th Street, New York, NY 10019. © Macquarie Group

Auckland	Bangkok	Calgary	<b>Denver</b>	Frankfurt	<b>Geneva</b>	Hong Kong
Tel: (649) 377 6433	Tel: (662) 694 7999	Tel: (1 403) 218 6650	Tel: (303) 952 2800	Tel: (069) 509 578 000	Tel: (41) 22 818 7777	Tel: (852) 2823 3588
<b>Jakarta</b>	Johannesburg	Kuala Lumpur	London	<b>Manila</b>	<b>Melbourne</b>	<b>Montreal</b>
Tel: (62 21) 515 1818	Tel: (2711) 583 2000	Tel: (60 3) 2059 8833	Tel: (44 20) 3037 2000	Tel: (63 2) 857 0888	Tel: (613) 9635 8139	Tel: (1 514) 925 2850
<b>Mumbai</b>	Munich	New York	<b>Paris</b>	<b>Perth</b>	<b>Seoul</b>	<b>Shanghai</b>
Tel: (91 22) 6653 3000	Tel: (089) 2444 31800	Tel: (1 212) 231 2500	Tel: (33 1) 7842 3823	Tel: (618) 9224 0888	Tel: (82 2) 3705 8500	Tel: (86 21) 6841 3355
<b>Singapore</b> Tel: (65) 6601 1111	<b>Sydney</b> Tel: (612) 8232 9555	<b>Taipei</b> Tel: (886 2) 2734 7500	<b>Tokyo</b> Tel: (81 3) 3512 7900	<b>Toronto</b> Tel: (1 416) 848 3500		

Available to clients on the world wide web at www.macquarieresearch.com and through Thomson Financial, FactSet, Reuters, Bloomberg, CapitallQ and TheMarkets.com.

# Macquarie **Equities Research**



# **Asia Research**

Head of Equity Research	
John O'Connell (Global Co – Head)	(612) 8232 7544
David Rickards (Global Co – Head)	(612) 8237 1159
Chris Hunt (Asia – Head)	(852) 3922 1119
Tim Smart (Asia – Deputy Head)	(852) 3922 3565
Automobiles/Auto Parts	
Amit Mishra (India)	(9122) 6720 4084
Clive Wiggins (Japan)	(813) 3512 7856
Dan Lucas (Japan) Michael Sohn (Korea)	(813) 3512 6050 (82 2) 3705 8644
Banks and Non-Bank Financi	
Ismael Pili (Asia, Hong Kong) Victor Wang (China)	(852) 3922 4774 (852) 3922 1479
Mudit Painuly (India)	(9122) 6720 4083
Suresh Ganapathy (India)	(9122) 6720 4078
Nicolaos Oentung (Indonesia)	(6221) 2598 8366
Alastair Macdonald (Japan)	(813) 3512 7476
Chan Hwang (Korea)	(822) 3705 8643
Matthew Smith (Malaysia, Singapore) Alex Pomento (Philippines)	(65) 6601 0981 (632) 857 0899
Jemmy Huang (Taiwan)	(8862) 2734 7530
Passakorn Linmaneechote (Thailand)	(662) 694 7728
Conglomerates	
Janet Lewis (Hong Kong)	(852) 3922 5417
Alex Pomento (Philippines)	(632) 857 0899
Consumer and Gaming	
Gary Pinge (Asia)	(852) 3922 3557
Linda Huang (China, Hong Kong)	(852) 3922 4068
Amit Mishra (India)	(9122) 6720 4084
Lyall Taylor (Indonesia)	(6221) 2598 8489
Toby Williams (Japan) HongSuk Na (Korea)	(813) 3512 7392 (822) 3705 8678
Alex Pomento (Philippines)	(632) 857 0899
Somesh Agarwal (Singapore)	(65) 6601 0840
Brandon Chen (Taiwan)	(8862) 2734 7518
Best Waiyanont (Thailand)	(662) 694 7993
Emerging Leaders	
Jake Lynch (China, Asia)	(8621) 2412 9007
Jonathan Hsu (China, Hong Kong)	(852) 3922 4625
Saiyi He (Hong Kong) Robert Burghart (Japan)	(852) 3922 3585 (813) 3512 7853
Makoto Egami (Japan)	(813) 3512 7879
Industrials	()
Janet Lewis (Asia)	(852) 3922 5417
Patrick Dai (China)	(8621) 2412 9082
Inderjeetsingh Bhatia (India)	(9122) 6720 4087
Juwon Lee (Korea)	(822) 3705 8661
Sunaina Dhanuka (Malaysia)	(603) 2059 8993 (662) 694 7753
David Gambrill (Thailand)	(002) 094 7755
	(050) 2002 2527
Scott Russell (Asia, China) Chung Jun Yun (Korea)	(852) 3922 3567 (822) 2095 7222
Media and Internet	(022) 2000 1222
Jiong Shao (China, Hong Kong)	(852) 3922 3566
Steve Zhang (China, Hong Kong)	(852) 3922 3566 (852) 3922 3578
Nitin Mohta (India)	(9122) 6720 4090
Prem Jearajasingam (Malaysia)	(603) 2059 8989
Alex Pomento (Philippines)	(632) 857 0899

# **Asia Sales**

Regional	Heads	of	Sales
Robin Black	(Asia)		

Chris Gray (ASEAN)
Peter Slater (Boston)
Jeffrey Shiu (China & Hong Kong)
Thomas Renz (Geneva)
Andrew Mouat (India)
Kenneth Yap (Indonesia)
JJ Kim (Korea)
Jason Lee (Malaysia)
Chris Gould (Malaysia)
Gino C Rojas (Philippines)
Greg Norton-Kidd (New York)
Luke Sullivan (New York)
Eric Roles (New York)
Sheila Schroeder (San Francisco)

#### **Oil, Gas and Petrochemicals**

Oil, Gas and Petrochemicals	
James Hubbard (Asia)	(852) 3922 1226
Jal Irani (India)	(9122) 6720 4080
Polina Diyachkina (Japan)	(813) 3512 7886
Sunaina Dhanuka (Malaysia)	(603) 2059 8993
Trevor Buchinski (Thailand)	(662) 694 7829
Pharmaceuticals and Health	care
Jonathan Hsu (Hong Kong)	(852) 3922 4625
Abhishek Singhal (India)	(9122) 6720 4086
Eunice Bu (Korea)	822) 2095 7223
Chinnarat Boonmahanark (Thailand)	(662) 694 7985
Property	
Callum Bramah (Asia)	(852) 3922 4731
David Ng (China, Hong Kong)	(852) 3922 1291
Jeffrey Gao (China)	(8621) 2412 9026
Unmesh Sharma (India)	(9122) 6720 4092
Felicia Barus (Indonesia)	(6221) 2598 8480
Hiroshi Okubo (Japan)	(813) 3512 7433
Sunaina Dhanuka (Malaysia)	(603) 2059 8993
Alex Pomento (Philippines)	(632) 857 0899
Tuck Yin Soong (Singapore)	(65) 6601 0838
Elaine Cheong (Singapore)	(65) 6601 0839
Corinne Jian (Taiwan)	(8862) 2734 7522
Brandon Chen (Taiwan)	(8862) 2734 7518
Patti Tomaitrichitr (Thailand)	(662) 694 7727
<b>Resources / Metals and Mini</b>	ng
Andrew Dale (Asia)	(852) 3922 3587
Graeme Train (China)	(8621) 2412 9035
Pelen Ji (China, Hong Kong)	(852) 3922 4741
Christina Lee (Hong Kong)	(852) 3922 3571
Rakesh Arora (India)	(9122) 6720 4093
Adam Worthington (Indonesia)	(852) 3922 4626
Polina Diyachkina (Japan)	(813) 3512 7886
Chak Reungsinpinya (Thailand)	(662) 694 7982
Technology	
Jeffrey Su (Asia, Taiwan)	(8862) 2734 7512
Lisa Soh (China)	(852) 3922 1401
Nitin Mohta (India)	(9122) 6720 4090
Damian Thong (Japan)	(813) 3512 7877
David Gibson (Japan)	(813) 3512 7880
George Chang (Japan)	(813) 3512 7854
Jeff Loff (Japan)	(813) 3512 7851
Michiko Kakiya (Japan)	(813) 3512 7868
Yukihiro Goto (Japan)	(813) 3512 5984
Daniel Kim (Korea)	(822) 3705 8641
Andrew Chang (Taiwan)	(8862) 2734 7526
Daniel Chang (Taiwan)	(8862) 2734 7516
Kylie Huang (Taiwan)	(8862) 2734 7528
Telecoms	
Nathan Ramler (Asia)	(813) 3512 7875
Lisa Soh (China, Hong Kong)	(852) 3922 1401
Riaz Hyder (Indonesia)	(6221) 2598 8486
Prem Jearajasingam	
(Malaysia, Singapore)	(603) 2059 8989
Alex Pomento (Philippines)	(632) 857 0899
Joseph Quinn (Taiwan)	(8862) 2734 7519
Best Waiyanont (Thailand)	(662) 694 7993

#### **Transport & Infrastructure**

Janet Lewis (Asia, Japan)	(852) 3922 5417
Nicholas Cunningham (Jap	
Sunaina Dhanuka (Malays	sia) (603) 2059 8993
Utilities & Renewabl	les
Adam Worthington (Asia)	(852) 3922 4626
Jeff Evans (India)	(9122) 6720 4081
Prem Jearajasingam (Mala	
Alex Pomento (Philippines	s) (632) 857 0899
Commodities	
Jim Lennon	(4420) 3037 4271
Duncan Hobbs	(4420) 3037 4497
Bonnie Liu	(65) 6601 0144
Graeme Train	(8621) 2412 9035
Rakesh Arora	(9122) 6720 4093
Data Services	
Andrea Dailly (Asia)	(852) 3922 4076
Eric Yeung	(852) 3922 4077
Economics	
Richard Gibbs (Australia)	(612) 8232 3935
Paul Cavey (China)	(852) 3922 3570
Renee Chen (Hong Kong,	
Tanvee Gupta (India)	(9122) 6720 3455
Quantitative / CPG	
Gurvinder Brar (Global)	(4420) 3037 4036
Viking Kwok (Asia)	(852) 3922 4735
Burke Lau (Asia)	(852) 3922 5494
Patrick Hansen (Japan)	(813) 3512 7876
Ayumu Kuroda (Japan)	(813) 3512 7569
Simon Rigney (Japan)	(813) 3512 7872
Strategy/Country	
Michael Kurtz (Asia)	(852) 3922 1403
Peter Eadon-Clarke (Asia,	Japan) (813) 3512 7850
Jiong Shao (China, Hong I	
Rakesh Arora (India)	(9122) 6720 4093
Nicolaos Oentung (Indone	
David Gibson (Japan)	(813) 3512 7880
Chan Hwang (Korea)	(822) 3705 8643
Kieran Calder (Malaysia)	(603) 2059 8992
Yeonzon Yeow (Malaysia)	
Alex Pomento (Philippines	
Conrad Werner (Singapore	
Daniel Chang (Taiwan) David Gambrill (Thailand)	(8862) 2734 7516
David Gambrill (Thailand)	(662) 694 7753
Find our research at	
	macquarie.com.au/research
	thomson.com/financial
Reuters: www.	knowledge.reuters.com

Macquarie:	www.macquarie.com.au/research			
Thomson:	www.thomson.com/financial			
Reuters:	www.knowledge.reuters.com			
Bloomberg:	MAC GO			
Factset:	http://www.factset.com/home.aspx			
CapitalIQ	www.capitaliq.com			
TheMarkets.com	www.themarkets.com			
Email macresearch@macquarie.com for access				

#### Regional Heads of Sales cont'd

	Regional modulo of ouroo	oont a	ealee maanig een
(852) 3922 2074 (65) 6601 0288 (1 617) 598 2502 (852) 3922 2061 (41) 22 818 7712 (9122) 6720 4100 (6221) 515 1555	Miki Edelman (Taiwan) Angus Kent (Thailand) Michael Newman (Tokyo) Angus Innes (UK/Europe) Rob Fabbro (UK/Europe) Sean Alexander (Generalist) Regional Head of Distribu	Mike Keen (Europe) Chris Reale (New York) Marc Rosa (New York) Stanley Dunda (Indones Kenneth Cheung (Mala Michael Santos (Philipp Isaac Huang (Taiwan)	
(822) 3705 8799 (603) 2059 8888	Justin Crawford (Asia)	(852) 3922 2065	Dominic Shore (Thailand Alternative Strateg
(603) 2059 8888 (632) 857 0861	Sales Trading		Convertibles - Roland Sh
(1 212) 231 2527 (1 212) 231 2527 (1 212) 231 2507 (1 212) 231 2559 (1 415) 762 5001	Adam Zaki (Asia) Yat Quan Tan (Hong Kong) Phil Sellaroli (Japan) Grace Lee (Korea) Matthew Ryan (Singapore)	(852) 3922 2002 (852) 3922 2028 (813) 3512 7837 (822) 3705 8601 (65) 6601 0288	Depository Receipts – Se Derivatives – Mark Hollar Structured Products - An

#### Sales Trading cont'd

	(44) 20 3037 4905
)	(1 212) 231 2555
	(1 212) 231 2555
sia)	(6221) 515 1555
ysia)	(603) 2059 8888
oines)	(632) 857 0813
	(8862) 2734 7582
nd)	(662) 694 7707

#### rategies

Convertibles - Roland Sharman	(852) 3922 2095
Depository Receipts – Seung-Jin Lee	(65) 6601 0203
Derivatives – Mark Holland	(852) 3922 2081
Structured Products - Andrew Terlich	(852) 3922 2013